Ernexa Therapeutics (NASDAQ:ERNA) Trading Up 3.4% – Here’s What Happened

Shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) rose 3.4% on Monday . The company traded as high as $4.01 and last traded at $3.96. Approximately 13,496 shares were traded during mid-day trading, a decline of 73% from the average daily volume of 50,284 shares. The stock had previously closed at $3.83.

Analysts Set New Price Targets

ERNA has been the subject of a number of recent research reports. Wall Street Zen cut shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ernexa Therapeutics currently has an average rating of “Hold” and a consensus target price of $30.00.

Ernexa Therapeutics Stock Performance

The company has a fifty day moving average of $4.39 and a two-hundred day moving average of $6.07. The company has a market cap of $5.95 million, a PE ratio of -0.25 and a beta of 2.61.

Ernexa Therapeutics (NASDAQ:ERNA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.30) by ($0.10). On average, equities analysts forecast that Ernexa Therapeutics Inc. will post -18.02 EPS for the current year.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.